A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV).
As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of herpes, HSV-1 and HSV-2.
Published on March 1, 2023, a peer-reviewed study disclosed Pritelivir was evaluated in five phase 1 trials, a single-ascending-dose trial, two multiple-ascending-dose trials, and others.
HSV Treatment Readies for Approval
Fatal Drug Overdose Down With OUD-Related Telehealth Services
Furthermore, risk for fatal drug overdose lower with receipt of medications for opioid use disorder from opioid treatment programs
WHO: Healthy Children, Teens May Not Need More COVID-19 Shots
Instead, COVID-19 vaccines should go to high-risk people, according to the agency’s Strategic Advisory Group of Experts on Immunization